GA
VRTX icon

GoalVest Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

GoalVest Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110
Closed -$49.1K – 562
2026
Q1 		$49.1K Buy
110
+10
+10% +$4.66K 0.01% 224
2025
Q4 		$45.3K Hold
100
– – 0.01% 254
2025
Q3 		$39.2K Hold
100
– – 0.01% 235
2025
Q2 		$44.5K Buy
100
+97
+3,233% +$44.7K 0.01% 219
2025
Q1 		$1.45K Buy
+3
New +$1.4K ﹤0.01% 318
2024
Q2 		– Sell
-11
Closed -$4.6K – 408
2024
Q1 		$4.6K Buy
+11
New +$4.65K ﹤0.01% 345
2022
Q2 		– Sell
-3
Closed -$1K – 542
2022
Q1 		$1K Buy
+3
New +$712 ﹤0.01% 370

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

GoalVest Advisory's VRTX Position: Q2 2026 in Review

GoalVest Advisory sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 110 shares — an estimated $49.1K sold.

GoalVest Advisory first reported a position in VRTX in Q1 2022 and held it in 7 quarters. The position peaked at $49.1K in Q1 2026. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • GoalVest Advisory reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GoalVest Advisory sold 110 Vertex Pharmaceuticals shares in Q2 2026, an estimated $49.1K.
  • GoalVest Advisory first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • GoalVest Advisory's Vertex Pharmaceuticals position peaked at $49.1K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GoalVest Advisory's 13F filing for Q2 2026, filed 9 Jul 2026.